Insulin Lispro Mix50 — Competitive Intelligence Brief

Insulin Lispro Mix50 (Insulin Lispro Mix50) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog, rapid-acting (premixed formulation). Area: Diabetes.

marketed Insulin analog, rapid-acting (premixed formulation) Insulin receptor Diabetes Small molecule

Target snapshot

Insulin Lispro Mix50 (Insulin Lispro Mix50) — Eli Lilly and Company. Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Lispro Mix50 TARGET	Insulin Lispro Mix50	Eli Lilly and Company	marketed	Insulin analog, rapid-acting (premixed formulation)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog, rapid-acting (premixed formulation) class)

1. Eli Lilly and Company · 1 drug in this class